These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7905033)

  • 41. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
    Thompson PA; Buckley PF; Meltzer HY
    J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
    Buchanan RW; Panagides J; Zhao J; Phiri P; den Hollander W; Ha X; Kouassi A; Alphs L; Schooler N; Szegedi A; Cazorla P
    J Clin Psychopharmacol; 2012 Feb; 32(1):36-45. PubMed ID: 22198451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Principal components and further possibilities with the PANSS.
    von Knorring L; Lindström E
    Acta Psychiatr Scand Suppl; 1995; 388():5-10. PubMed ID: 7541600
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prodromal states in schizophrenia.
    Gaebel W; Jänner M; Frommann N; Pietzcker A; Köpcke W; Linden M; Müller P; Müller-Spahn F; Tegeler J
    Compr Psychiatry; 2000; 41(2 Suppl 1):76-85. PubMed ID: 10746908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness.
    Rabinowitz J; Levine SZ; Medori R; Oosthuizen P; Koen L; Emsley R
    Schizophr Res; 2008 Mar; 100(1-3):359-60. PubMed ID: 18077138
    [No Abstract]   [Full Text] [Related]  

  • 46. Spanish validation of the Negative Symptom Assessment-16 (NSA-16) in patients with schizophrenia.
    Garcia-Alvarez L; Garcia-Portilla MP; Saiz PA; Fonseca-Pedrero E; Bobes-Bascaran MT; Gomar J; Muñiz J; Bobes J
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(3):169-175. PubMed ID: 29628403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale.
    Mass R; Schoemig T; Hitschfeld K; Wall E; Haasen C
    Schizophr Bull; 2000; 26(1):167-77. PubMed ID: 10755679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia.
    Peralta V; Cuesta MJ
    Psychiatry Res; 1994 Jul; 53(1):31-40. PubMed ID: 7991730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS.
    Preda A; Nguyen DD; Bustillo JR; Belger A; O'Leary DS; McEwen S; Ling S; Faziola L; Mathalon DH; Ford JM; Potkin SG; ; van Erp TGM
    Schizophr Res; 2018 Nov; 201():113-119. PubMed ID: 29935887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The dimensions of schizophrenia phenomenology. Not one or two, at least three, perhaps four.
    Lenzenweger MF; Dworkin RH
    Br J Psychiatry; 1996 Apr; 168(4):432-40. PubMed ID: 8730939
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positive and negative symptoms in neuroleptic-free psychotic inpatients.
    Stuart GW; Malone V; Currie J; Klimidis S; Minas IH
    Schizophr Res; 1995 Aug; 16(3):175-88. PubMed ID: 7488563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Examining the underlying structure of schizophrenic phenomenology: evidence for a three-process model.
    Lenzenweger MF; Dworkin RH; Wethington E
    Schizophr Bull; 1991; 17(3):515-24. PubMed ID: 1947875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validating specific psychopathology scales in older outpatients with schizophrenia.
    McAdams LA; Harris MJ; Bailey A; Fell R; Jeste DV
    J Nerv Ment Dis; 1996 Apr; 184(4):246-51. PubMed ID: 8604035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
    Nasrallah H; Morosini P; Gagnon DD
    Psychiatry Res; 2008 Nov; 161(2):213-24. PubMed ID: 18848731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reliability and validity of the Medication Adherence Rating Scale in a cohort of patients with schizophrenia from Nigeria.
    Owie GO; Olotu SO; James BO
    Trends Psychiatry Psychother; 2018; 40(2):85-92. PubMed ID: 29768528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Depression measures and motor side-effects in patients with acute schizophrenia.
    Kontaxakis VP; Havaki-Kontaxaki BJ; Stamouli SS; Margariti MM; Kollias CT; Christodoulou GN
    Schizophr Res; 2002 Jul; 56(1-2):197-8. PubMed ID: 12084435
    [No Abstract]   [Full Text] [Related]  

  • 57. Negative symptoms in chronic schizophrenia. Relationship to duration of illness.
    Ring N; Tantam D; Montague L; Morris J
    Br J Psychiatry; 1991 Oct; 159():495-9. PubMed ID: 1751858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is social skills performance a correlate of schizophrenia subtypes?
    Jackson HJ; Minas IH; Burgess PM; Joshua SD; Charisiou J; Campbell IM
    Schizophr Res; 1989; 2(3):301-9. PubMed ID: 2487170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment.
    Czobor P; Volavka J
    Compr Psychiatry; 1996; 37(3):205-15. PubMed ID: 8732588
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy.
    Peralta V; de Leon J; Cuesta MJ
    Br J Psychiatry; 1992 Sep; 161():335-43. PubMed ID: 1356572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.